Thrombosis research
-
Thrombosis research · Apr 2010
Trends in mortality of pulmonary embolism--an international comparison.
Evidence from several clinical and epidemiological studies suggests a decreasing incidence and mortality of pulmonary embolism (PE), but results are still controversial. We analysed time trends of fatal pulmonary embolism in several countries across Europe and North America. ⋯ While comparison of cause of death data over time and across countries should be undertaken with caution due to inaccuracies in assigning the cause of death and national conventions in coding, the general trend of a decline in PE mortality could not be shown in several European countries.
-
Thrombosis research · Mar 2010
Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model.
Fluid resuscitation after trauma often results in dilutional coagulopathy that may hinder control of bleeding and, once initial hemostasis has been secured, heighten risk of perioperative bleeding when further surgery is required. Since multiple coagulation factor deficiencies typically accompany fluid resuscitation, prothrombin complex concentrate (PCC) containing factors II, VII, IX and X may potentially offer greater hemostatic efficacy than coagulation factor monotherapy. ⋯ In an animal model of dilutional coagulopathy and kidney trauma, PCC accelerated hemostasis and diminished blood loss compared with rFVIIa monotherapy.
-
Thrombosis research · Mar 2010
Randomized Controlled Trial Multicenter StudyBolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism.
The clinical benefit of thrombolytic treatment over heparin in patients with pulmonary embolism without hemodynamic compromise remains controversial. In these patients bolus tenecteplase has the potential to provide an effective and safe thrombolysis. ⋯ In hemodynamically stable patients with PE, treatment with single bolus tenecteplase is feasible at the same dosages used for acute myocardial infarction and is associated with reduction of RVD at 24 hours. Whether this benefit is associated with an improved clinical outcome without excessive bleeding is currently explored in a large clinical trial.
-
Thrombosis research · Mar 2010
The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease.
Monoclonal gammopathy of undetermined significance (MGUS) has been proposed to be a risk factor for venous thromboembolic disease (VTE). However, no series published to date has been population-based or included a control group with similar comorbidities to people with MGUS. ⋯ Our results suggest that the increased rate of VTE in people with MGUS may be primarily due to other underlying conditions that led to testing for a monoclonal gammopathy rather than to the monoclonal gammopathy itself.